Royalty Pharma plc - Class A risk profile
29 Normal where most of the sector sits
Measured 1 September 2026 from RPRX's filed statements. Recomputed nightly.
29 (Normal), driven by Leverage and coverage at 46, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 16 | Contained | Stable | One-year price volatility — 22.9% |
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | 0 | Contained | Stable | Free-cash-flow margin — 104.7% |
| Leverage and coverage | 46 | Elevated | Stable | Net debt to EBITDA — 5.09x |
| Competitive position | 33 | Normal | Stable | Revenue-growth gap against peers — -23.7 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Royalty Pharma plc - Class A